Production & Manufacturing
Press Releases
Lonza’s API Mid-Scale Manufacturing Facility Expansion in Nansha Enters Commercial Operation
Lonza announces the start of new mid-scale manufacturing assets at its API manufacturing center in Nansha, China. Commercial mid-scale operations are now underway at the expanded manufacturing facility, which was part of a CHF 20 million investment announced in...
News
How ‘First-Time Right’ Formulations Can Help Address the Challenge of Affordable Medicines
For years, global healthcare systems have been facing the triple threat of rising incidences of long-term conditions (LTC), aging populations and dwindling resources. At the same time, we have seen worldwide calls for affordable medicines – from the Jan...
News
By 2030, OSD Contract Manufacturing Will Be $54.7 Billion
The global oral solid dosage (OSD) contract manufacturing market is anticipated to reach $54.7 billion in value by 2030, exhibiting a compound annual growth rate (CAGR) of 6%, according to a market analysis.
As per data, oral solids are the...
News
By 2026, Pharma Contract Manufacturing To Be Worth $130bn
The global pharmaceutical contract manufacturing market is anticipated to reach $130.2 billion by 2026 as a result of increasing demand for pharmaceuticals, particularly in developing economies. In 2020, the market was estimated to be worth $100 billion.
Market research indicates...
News
Leanings In The Biopharma Contract Manufacturing For 2022
A recent survey found that 86.9% of biopharmaceutical businesses outsource at least a portion of their operations, which has contributed to the $14 billion market for biopharmaceutical contract manufacturing.
Over the next ten years, the investigators predict a very bright...
News
FTC Aims Manufacturer, PBM Rebates For Rising Insulin Costs
Bribes and rebate arrangements involving drugmakers and pharma middlemen are all being investigated by US regulators, with a particular focus on rising insulin prices. The Federal Trade Commission (FTC) announced recently that it would step up enforcement against practises...
News
Pfizer Commits $120mn In COVID-19 U.S. Oral Drug Production
COVID-19's propensity to fuel domestic drug production hasn't waned two years into the pandemic. Take, for example, Pfizer's new $120 million investment. The company announced on June 6Â that it will use the funds to expand manufacturing of its oral...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read